503614-91-3

Basic information

• Product Name: 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
• Synonyms: 1H-Pyrazolo[3,4-c]pyridine-3-carboxylicacid,4,5,6,7-tetrahydro-1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-,ethylester;4,5,6,7-Tetrahydro-1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1h-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester;Apixaba inretMediate C;ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate;Apixaban Impurity 7;-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate;-7-oxo-6-(4-(2-oxopiperidin-1-yl);Ethyl 1-(4-methoxyphenyl)
• CAS NO: 503614-91-3
• Molecular Formula: C₂₇H₂₈N₄O₅
• Molecular Weight: 488.53502
• EINECS: 1592732-453-0
• Mol File: 503614-91-3.mol
• Article Data: 37

Chemical Properties

• Boiling Point: 758.7±60.0 °C(Predicted)
• Appearance: /
• Density: 1.34
• Vapor Pressure: 0.001Pa at 25℃
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 0.78±0.20(Predicted)
• CAS DataBase Reference: 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester(503614-91-3)
• EPA Substance Registry System: 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester(503614-91-3)

Safety Data

• Hazardous Substances Data: 503614-91-3(Hazardous Substances Data)

Usage

Uses

Apixaban V is a derivative of Apixaban (A726700), a potent, direct, selective, and orally active inhibitor of coagulation factor Xa. It is a potential new oral coagulant that may be useful prevention of venous thromboembolism in total hip, knee replacement orthopedic surgery and stroke in treatment of patient with venous thromboembolic disorder or with atrial fibrillation

Upstream product

• 881386-12-5 ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(5-bromovaleroylamino)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate 
• 1609409-53-1 ethyl {5-hydroxy-6-oxo-1-[4-(2-oxopiperidin-1-yl)phenyl]-1,2,3,6-tetrahydropyridin-4-yl}(oxo)acetate 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 454183-28-9 3-(4-nitrophenylamino)propionic acid ethyl ester 
• 545445-40-7 3-morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one 
• 473927-63-8 ethyl (2Z)-chloro[2-(4-methoxyphenyl)hydrazinylidene]ethanoate 
• 385425-15-0 1-(2-oxopiperidin-1-yl)-4-iodobenzene 
• 503614-56-0 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3, 4-c]pyridine-3-carboxylic acid ethyl ester 
• 41419-12-9 3,3-dichloro-piperidin-2-one 
• 207976-92-9 3-chloro-5,6-dihydro-1H-pyridin-2-one 
• 675-20-7 piperidin-2-one 
• 1575-61-7 5-Chlorovaleroyl chloride 
• 4509-90-4 5-bromovaleroyl chloride 
• 536760-29-9 3-chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one 

Downstream Products

• 503612-86-0 1-(4-methoxyphenyl)-3-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-6-(4-(2-oxopiperidin-1-yl)phenyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one 
• 503612-88-2 1-(4-methoxyphenyl)-3-methyl-6-[4-(2-oxopiperidin-1-yl)-phenyl]-1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one 
• 503612-90-6 3-(1-hydroxy-1-methylethyl)-1-(4-methoxyphenyl)-6-[4-(2-oxopiperidin-1-yl)phenyl]-1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one 
• 503614-92-4 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 
• 503612-45-1 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile 

Relevant articles and documents

Synthesis method of apixaban intermediate

The invention discloses a synthesis method of an apixaban intermediate; the high-yield apixaban intermediate II is obtained by changing the reaction conditions of the apixaban intermediate, so that the yield of the apixaban is improved; specifically, raw materials a and b are subjected to an addition reaction in a toluene solution through base catalysis, after the reaction is completed, an elimination reaction is performed under the action of acid, and then a final product II is obtained through the processes of extraction, washing, concentration, refining and the like.

Method for preparing apixaban crystal form

The invention relates to a method for preparing an apixaban crystal form N-1. The method is characterized by comprising the following steps: adding an apixaban compound into a 85-95% C1-6alkyl alcohol, performing dissolution, performing crystal separation, performing filtering and washing, and performing drying, so as to obtain the target crystal form N-1. By adopting the technical scheme of the invention, a crystal conversion solvent is simple and easy to obtain, the operation method is simple, the condition is mild, equipment is not specifically required, special reaction condition and equipment are not needed, and the method is applicable to industrial production.

Preparation process of high-purity apixaban

The invention discloses a preparation process of apixaban. The method comprises the following steps of: performing amidation on an initial raw material compound (IV) and delta-valerolactone under pressure; performing a one-pot reaction on the obtained hydroxyl amide and p-toluenesulfonyl chloride (PTSC)to obtain a compound (III); carrying out a reaction with tetrabutylammonium fluoride trihydrateto obtain a cyclization product compound (II); preparing a compound (I) from 2,4-dichlorobenzaldehyde and formamide under the action of sodium methoxide and a molecular sieve; refining the crude product by adopting an optimized ethanol/dichloromethane mixed solvent, so that impurity A is removed well; by means of the method, the apixaban product with high yield and high purity is prepared, whereinthe purity of the apixaban product is not lower than 99.5%, the impurity A does not exceed 0.05%, and any single impurity does not exceed 0.1%.